Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01951625 · ClinicalTrials.gov registry record · Phase 2
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
A Phase 2 study of Heart Failure, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 456
- Enrollment target
- 20
- Study locations
NCT01951625: Completed Phase 2 study of Heart Failure, sponsored by Bayer.
NCT01951625 is a Phase 2 study of Heart Failure that has completed, run by Bayer. The registered enrollment target is 456 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01951625, a Phase 2 study of Heart Failure, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 456 participants
- Enrollment target
- 20
- Study locations
Study Summary
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).
Primary Outcome
Log-Transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) is a circulating plasma biomarker of cardiovascular function and prognosis in heart failure.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vericiguat (BAY1021189) (1.25 mg)
- DRUG Vericiguat (BAY1021189) (5 mg)
Study Locations (20)
Florida
- - Fort Lauderdale
- - Jacksonville
- - Naples
Georgia
- - Atlanta
- - Macon
Ohio
- - Columbus
- - Fairfield
Tennessee
- - Germantown
- - Nashville
California
- - Fountain Valley
Delaware
- - Wilmington
Louisiana
- - New Orleans
Michigan
- - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2013-11-29 |
| Est. Completion | 2015-06-09 |
| Phase | Phase 2 |
What the finished NCT01951625 record still lists
NCT01951625 is an interventional study that assigns participants to a tested intervention. The registered 456 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01951625 names 20 study sites across 15 states, led by Florida, Georgia, Ohio.
Frequently Asked Questions
What is clinical trial NCT01951625 about?
NCT01951625 is a clinical study titled "Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)". Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).
What is the current status of trial NCT01951625?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 456 participants. The study started on 2013-11-29. Estimated completion is 2015-06-09.
What conditions does trial NCT01951625 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT01951625?
The interventions under investigation include: Placebo (DRUG), Vericiguat (BAY1021189) (1.25 mg) (DRUG), Vericiguat (BAY1021189) (5 mg) (DRUG).
Who is sponsoring clinical trial NCT01951625?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01951625 being conducted?
This trial has 20 study locations across California, Delaware, Florida, Georgia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01951625's enrollment target sits among peer trials
456 110th of 397 higher than 288 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
RECRUITING · Phase 2
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 2
-
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
-
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04462302 · 456 participants · NA
An Internet-based Program to Help Cancer Survivors Manage Pain
- NCT05820919 · 456 participants · NA
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
- NCT06254612 · 456 participants · Phase 2
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
- NCT06457841 · 456 participants · NA
Stress and Resilience
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI